IL6 and familial pancreatic carcinoma: The upregulation of IL6 44-46 and PD-L1 47 pathways could negatively impact anti-tumor immunity, providing the rationale for combining OV-mOX40L with neutralizing antibodies against IL6 or PD-L1 pathways for the treatment of pancreatic cancer.